window.pageData = {"stock":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50940000","tickerId":50940000,"name":"嘉合基金管理有限公司"},"hotMetrics":{"fp":{"stockId":3000000007613,"type":"fp","last_data_date":"2022-10-27T16:00:00.000Z","f_p_r_fys":-0.2983137455288707,"f_p_r_m1":0.0005829204313609893,"f_p_r_m3":-0.13231391381271318,"f_p_r_m6":-0.07888382076737321,"f_p_r_y1":-0.26338375710760653,"f_p_r_y2":-0.2965374567517326,"f_p_r_y3":0.005187318191310908,"f_cagr_p_r_fs":0.003586088631444939}},"masterSlaveFunds":[]},"list":[{"_id":"69aecae87fea5b3eb04ab902","date":"2022-06-29T16:00:00.000Z","stockId":3000000007613,"sao":"回顾市场，医药行业本轮的调整自21年7月的高位起开始计算，调整的力度之大和时间之长都实属罕见。在今年4月份，在国内外新冠疫情反复、海外市场环境等多重因素的影响下，医疗服务及医药服务作为前期医药板块的典型支柱性产业都遭受到了甚至极端的打击。在多重意外事件的叠加下并且由于今年上半年市场整体的快速下跌导致的投资者风险偏好下行，医药行业随整体成长风格股票持续下行。但当下我们观察到医药行业诸多积极信号：仿制药行业的业绩基于季报等信息已表现出见底信号；海外创新药等股价陆续出现反弹等，因此在5月6月的行情中，医药板块的反弹力度也在市场各行业中居前；我们在投资中将坚持高端制造的路线，继续延续侧重创新药、中药等细分行业的配置，并精选业绩稳定向好的板块来构建组合，力求为投资者创造良好的回报。","declarationDate":"2022-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.583Z","mo":"从未来的市场风格角度，我们看好下一阶段成长风格的表现。在国内市场，7月28日的政治局会议明确了稳增长基调不变，政策的边际增量在宽信用，我们认为经济最差的时刻已经过去；而海外市场方面，市场对于美联储加息的顾虑大幅消退。从A股一季度调整后的大幅上行和美股走强也得到初步印证。医药板块目前的估值水平和在公募基金的配置比例都处于历史的极低位置，我们认为疫情稳定后，如医疗服务等板块已经出现边际改善，且结合部分政策预期向好，下半年市场对于医药行业从过分悲观认知到正常认知的修复转化过程中，将孕育着相关的投资机会。","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=783912","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab901","date":"2022-03-30T16:00:00.000Z","stockId":3000000007613,"sao":"医药行业一季度经历了较大的波动，我们的投资策略也紧跟着市场变化相应做出调整。1月市场核心资产纷纷进入调整期。前期热门的中药概念等陆续开始出现回调，叠加生长素受集采等因素影响，我们调低了医药消费品在组合中的权重，陆续将权重调整至受益于Omicron病毒防治的相关概念标的，如疫苗、检测试剂等。随之3月受外部环境变化影响，医药板块再次出现短期剧烈调整。我们看好医药板块目前较低的估值及未来长期的表现，仍维持了较高的仓位。一季度末发布的十四五中医药发展规划，我们观察到部分中医药股已有表现；以及临近年报及一季报发布期，我们也会在组合中关注业绩强势的板块及个股，力求为投资者创造良好的体验。","declarationDate":"2022-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.581Z","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2022年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=725939","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab900","date":"2021-12-30T16:00:00.000Z","stockId":3000000007613,"sao":"医药行业自21年7月起至今已经调整了近半年的时间，受医保政策和疫情影响，各细分板块估值分化严重。医药行业应为受周期影响较弱的成长行业，但在排除保持高景气的CXO板块后，仍有很多细分板块的估值和溢价率处于历史中位数以下的区间。基于此，当期我们构建组合过程中侧重，一方面高景气且政策影响较弱的创新药、生物制药等板块；另一方面，在人口老龄化、居民收入水平提高的背景下，品牌优势明显的医疗服务企业和受益于行业集中度提升的医药零售子版块。我们将业绩作为医药板块的核心选股指标，选取高增长的细分领域和相关公司构建我们的投资组合，力求为投资者创造长期稳健的回报。","declarationDate":"2022-01-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.578Z","mo":"21年下半年以来，由于机构重仓的医药板块受到医保和医疗器械领域相继出台的价格政策、CXO板块融资数据的波动和海外事件等因素影响下陆续出现边际变化，医药板块整体进入下行周期，我们观察到机构医药持仓已经进入历史低位、板块估值也已经降至低位水平、市场目前预期也是极低。正基于此，我们认为当前医药板块已经处于底部位置，具备投资价值。投资组合的构建上，对于行业内投资，我们持续关注政策压力较小、需求端保持较快增长、供给端竞争格局良好的行业和相关企业：如CXO目前订单需求旺盛、产能扩张快速，是目前医药行业中同时具备高业绩确定性和成长型的行业；另外生命科学上游产业目前积极推进国产替代，从而具备性价比优势，细分行业景气度持续上行。同时，从短期来看，业绩是医药板块的核心驱动力，一季报业绩将作为我们判断和选择细分行业的重要参照和指标，我们将持续关注市场和相关企业变化。","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=713161","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8ff","date":"2021-09-29T16:00:00.000Z","stockId":3000000007613,"sao":"医疗行业在2021年三季度表现总体上先抑后扬，子版块分化较为明显。8月份在社零总额增速放缓走弱的大环境下，中西药品类消费增速仍然保持10%以上的稳定增长，充分体现了药品板块的刚需属性；与此同时医保支付端也保持稳定增长，传递至生产端保持加速恢复态势。9月后医药板块整体触底反弹，同期跑赢大盘指数，仍稍弱与部分周期、消费股。医药板块子行业方面，前期回调较为充分、估值回至相对合理水平的医疗服务子版块表现最为亮眼，而估值仍较高的疫苗板块大幅下跌。针对整个板块大幅回调后已处于估值相对合理区间，我们在当期构建投资组合上主要基于两条主线进行投资。首先，得益于政策引导，倒闭企业向创新转型，我们在组合内优选医药行业内研发实力雄厚、储备梯度丰富、产品优势突出的创新药龙头企业；其次，在创新药研发等多因素推动下，CXO行业高速发展，我们持续关注受益于行业集中度提升的行业及细分行业龙头个股。辅以高端医疗器械进口替代等业绩有显著表现的公司充实我们的组合，力求为投资者创造长期稳健的回报。","declarationDate":"2021-10-26T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.576Z","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2021年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=653860","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8fe","date":"2021-06-29T16:00:00.000Z","stockId":3000000007613,"sao":"2021年第一季度，以2月中旬中国农历春节为界，指数呈现先扬后抑、市场风格明显切换。在经历了第一季度的波动后，医药行业在二季度迎来了持续走高。走强的原因主要得益于行业内公司的业绩普遍向好。根据我们的统计，在申万医药行业389家上市公司中，净利润增长超100%的公司接近三分之一；总计316家企业都实现了利润的增加。除此之外，整个医药行业也是亮点不断：受益于创新药崛起和国际订单需求转移，国内CXO行业景气度持续提升；疫苗行业进入创新疫苗品种驱动下的高速成长期，整个板块我们认为可以期待长期高增长；医疗器械龙头公司竞争优势也逐渐凸显。我们认为由于医药行业景气度处于上行周期，细分板块集中度不断提升，强者恒强的现象明显；与此同时医药产业目前进入深层次转型期，创新药、拥有技术难度的高壁垒产品将成为大势所趋。所以我们在组合构建时侧重选择创新药布局丰富、创新产业链相关企业进行布局。除此之外，由于海外疫情仍在蔓延，因此在组合中我们仍保持了一定疫情相关标的的权重。综上，本基金在报告期末单位净值为1.5907，其中第二季度净值增长率为7.49%。","declarationDate":"2021-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.573Z","mo":"今年下半年的宏观市场环境，我们认为可能将不会呈现显著变化，整体将处于盈利较强和流动性稳中略宽松的环境中。结合已经发布的部分上市企业中报来看，整体经济将仍具相当的韧性，叠加较高的通胀水平下，我们预测下半年经济增长和企业盈利都有望持续超预期；政策方面，2021年7月30日，中共中央政治局会议上提出，做好宏观政策跨周期调节，保持宏观政策连续性、稳定性、可持续性，统筹做好今明两年宏观政策衔接，保持经济运行在合理区间。在新能源汽车、碳中和、制造业、高新技术产业和中小企业等方向更持续有相关利好政策推出。整体市场估值方面，宽基指数静态市盈率分位数在中位数水平，处于相对安全位置。需要注意的是，部分热门板块处于历史高位，资金相对集中，需要时间消化，我们预计也将在短期内限制大盘指数冲高的可能性。医药板块方面，近期出现了比较大幅度的调整，主要是市场担忧集采降价等因素影响。我们认为考虑到市场已经经历多轮医保谈判和集采降价，相关标的估值已经得到了充分的反映。考虑到政策的连贯性，短期内相关标的受到的影响也是可控的。除此以外，医药板块中景气度较高的细分领域，如CXO、医疗服务、第三方检测仍旧长期向好，在相关企业的业绩预告和中报中也得以体现。因此在下半年的投资中，我们将着重关注上述高景气板块的投资机会。","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=634932","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8fd","stockId":3000000007613,"sao":"一季度，随着疫苗接种的快速推进，全球疫情初步得以遏制，各国经济缓慢复苏，而国内经济预计将呈现强劲复苏态势，但随之而来的是通胀预期的抬头以及长端利率的上行，叠加流动性边际收紧的政策预期，给春节后的权益市场带来了较大冲击。以医药、科技、消费为代表的新兴成长板块快速杀跌，而以上游资源品、中游钢铁、化工等为代表的周期板块涨幅较大，两者估值差快速收敛，市场风格从去年的极度分化走向再平衡，背后反映的是投资者对于宏观经济强劲复苏的预期以及利率边际回升环境下估值泡沫化的担忧。在这样的背景下，本基金适时在仓位结构上作出了一定的调整，适度增持了一批顺周期标的，对于前期估值过高，业绩不及预期的个股作出了一定的减持，持仓风格更加均衡。考虑到今年的市场环境，预计挑选投资标的的难度将显著高于去年，本基金将坚持自下而上精选个股的投资策略，夯实研究工作，努力挖掘更多更好的投资机会，为投资者持续创造价值。","date":"2021-03-30T16:00:00.000Z","declarationDate":"2021-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.570Z","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2021年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=573740","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8fc","stockId":3000000007613,"sao":"2020年，一场突如其来的新型冠状肺炎大流行病席卷全球，给全球的政治经济生活带来了深刻影响，二季度以来，除中国以外的全球经济几乎处于停摆状态，这使得本就处于下滑态势的全球经济雪上加霜。为应对疫情带来的负面冲击，各国纷纷出台了积极的货币财政政策以稳定就业及经济秩序，全球步入新一轮的流动性宽松周期，资产价格进一步推升，长期通胀压力逐渐凸显。而国内在社会各界共同努力下，新冠疫情得到有效遏制，经济得以率先复苏，2020年GDP首次突破百万亿元大关，同比增长2.3%，是主要国家和地区中唯一录得正增长的经济体，海内外巨大的疫情反差带动了出口需求，2020年我国货物贸易进出口总值达到32.2万亿人民币，创出历史新高。相对宽松的流动性环境叠加经济复苏的乐观预期，催生了权益市场的良好表现，上证50全年上涨18.8%，沪深300指数上涨27.2%，创业板指数更是大涨65%。但也可以看到，指数间表现分化显著，以科技、医药、消费为代表的成长板块表现显著优于以金融、基建等为代表的传统周期板块，两者静态估值差创出历史新高，背后反映的是经济结构转型升级的强大预期以及宽松流动性下对于优质资产的极致追捧。在这样的市场环境下，本基金坚持自下而上精选个股的投资策略，全年维持高仓位运作，并重点配置了以创新药产业链为主的高景气医药板块，取得了良好的收益表现。未来本基金将坚持这一策略，挖掘更多投资机会，力争为投资人实现更多投资回报。","date":"2020-12-30T16:00:00.000Z","declarationDate":"2021-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.568Z","mo":"展望2021年，随着各国新冠疫苗的成功研发，市场对于经济复苏的预期有望得以强化，新经济为代表的成长板块与传统经济为代表的价值板块间巨大的估值差可能将有所收敛，市场风格可能将从极致成长向更加均衡的方向转变，我们将重点关注受益于经济复苏且前期因为市场风格而被错杀的优质标的。","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2020年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=560650","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8fb","stockId":3000000007613,"sao":"报告期内，经济延续了二季度以来的复苏态势，市场开始重视受益经济复苏的周期性行业中的部分机会，而前期持续表现优异的科技、医药、消费类股票偏于震荡整理。期间，我们严格按照本基金合同的约定来进行投资运作，基金资产着力配置在医疗健康领域相关个股。选股标准上，特别注重上市公司所处细分赛道的景气度和潜在发展空间，以及企业本身的经营模式、核心竞争力、成长的持续性和业绩确定性等方面。","date":"2020-09-29T16:00:00.000Z","declarationDate":"2020-10-27T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.565Z","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2020年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=489680","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecae87fea5b3eb04ab8fa","stockId":3000000007613,"sao":"报告期内，国内外新冠疫情爆发，2月底以来国内疫情逐渐得到控制，市场恐慌情绪也逐渐得到平复。期间，我们严格按照本基金合同的约定来进行投资运作，顺利度过建仓期；基金资产着力配置在医疗健康领域相关个股。选股标准上，特别注重企业所处赛道的潜在发展空间、企业的核心竞争力、企业成长的持续性和业绩确定性等方面。得益于我们配置品种基本都是业内有强竞争力、业绩增长较为确定的品种，产品逐渐收复疫情导致的净值失地后尚有进一步抬升。","date":"2020-06-29T16:00:00.000Z","declarationDate":"2020-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:28:08.563Z","mo":"得益于中国超高疫情控制水平，国内率先实现复工复产的有序推进以及经济形势的逐步好转，中国体制和市场的吸引力变得更强。从二季度各月数据来看，预计企业盈利在今年下半年实现复苏也将是大概率事件。但海外疫情等因素也需警惕，并需观察其对国内经济复苏力度和持续性的影响。后市而言，在流动性充裕、不断有增量资金入市、医疗板块成长性占优背景下，我们坚定看好板块的长期投资价值。从现有已发布的中期业绩预告和我们的研究看，板块内公司的中期业绩普遍较好，优质公司有未来成长的长逻辑、业绩也几乎是所有行业中最为刚性和强劲的。我们将沿着既定三大主线，充分挖掘板块机会。比如：第一，一季度未受疫情冲击的或者直接受益的公司，以及复工复产后快速复苏的那些公司。第二，疫苗研发和配套链条上的企业。第三，创新器械、创新药、医疗服务等确定景气向上的产业链公司。第四，部分低估值滞涨品种有价值重估潜力，可以寻找其中的绝对收益品种。","fund":{"_id":3000000007613,"stockCode":"007613","stockType":"fund","areaCode":"cn","followedNum":1,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-07-25T16:00:00.000Z","setUpScale":104423000,"market":"a","tickerId":7613,"custody":"中国工商银行股份有限公司","name":"嘉合医疗健康混合型发起式证券投资基金","shortName":"嘉合医疗健康混合","fundSecondLevel":"hybrid","__csrcFundId":6466,"fundStatus":"normal","lastUpdated":"2023-10-14T10:50:20.148Z","masterFundFlag":1,"inceptionDate":"2019-09-25T16:00:00.000Z","fundCollectionId":4000050940000,"currency":"CNY","masterFundShortName":"嘉合医疗健康混合","delistedDate":"2022-10-27T16:00:00.000Z"},"announcement":{"linkText":"嘉合医疗健康混合型发起式证券投资基金2020年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=459030","linkType":"PDF","source":"csrc_pdf"}}]}